
IMVT
Immunovant Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
17.310
Open
16.320
VWAP
16.86
Vol
4.51M
Mkt Cap
2.90B
Low
15.310
Amount
76.08M
EV/EBITDA(TTM)
--
Total Shares
146.05M
EV
2.42B
EV/OCF(TTM)
--
P/S(TTM)
--
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q2
FY2026Q1
--
--
-0.726
-4.53%
--
--
-0.710
-4.05%
--
--
-0.686
+14.26%
Estimates Revision
Stock Price
Go Up

+9.92%
In Past 3 Month
10 Analyst Rating

145.84% Upside
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 41.67 USD with a low forecast of 18.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy

145.84% Upside
Current: 16.950

Low
18.00
Averages
41.67
High
58.00

145.84% Upside
Current: 16.950

Low
18.00
Averages
41.67
High
58.00
Goldman Sachs
Neutral
maintain
$18
2025-07-10
Reason
Goldman Sachs
Price Target
$18
2025-07-10
maintain
Neutral
Reason
Goldman Sachs resumed coverage of Immunovant with a Neutral rating and $18 price target. The firm sees limited downside but also a challenging regulatory backdrop for the company.
H.C. Wainwright
Buy
downgrade
$51 -> $35
2025-05-30
Reason
H.C. Wainwright
Price Target
$51 -> $35
2025-05-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Immunovant to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company's data readouts in 2027, with an expected potential launch in 2028.
UBS
Colin Bristow
Strong Buy
to
Hold
Downgrades
$38 → $17
2025-04-22
Reason
UBS
Colin Bristow
Price Target
$38 → $17
2025-04-22
Downgrades
Strong Buy
to
Hold
Reason
UBS downgraded Immunovant to Neutral from Buy with a price target of $17, down from $38.
B of A Securities
Jason Gerberry
Strong Buy
Maintains
$38 → $33
2025-03-20
Reason
B of A Securities
Jason Gerberry
Price Target
$38 → $33
2025-03-20
Maintains
Strong Buy
Reason
Guggenheim
Yatin Suneja
Strong Buy
Reiterates
n/a
2025-03-20
Reason
Guggenheim
Yatin Suneja
Price Target
n/a
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$51
2025-03-19
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$51
2025-03-19
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Immunovant Inc (IMVT.O) is -6.43, compared to its 5-year average forward P/E of -11.89. For a more detailed relative valuation and DCF analysis to assess Immunovant Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-11.89
Current PE
-6.43
Overvalued PE
-2.86
Undervalued PE
-20.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-9.72
Current EV/EBITDA
-5.07
Overvalued EV/EBITDA
-0.93
Undervalued EV/EBITDA
-18.51
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
12.00
Current PS
329.87
Overvalued PS
68.36
Undervalued PS
-44.36
Financials
Annual
Quarterly
FY2025Q4
YoY :
+40.73%
-113.83M
Operating Profit
FY2025Q4
YoY :
+41.33%
-106.45M
Net Income after Tax
FY2025Q4
YoY :
+23.08%
-0.64
EPS - Diluted
FY2025Q4
YoY :
+85.20%
-110.84M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
140.4K
USD
4
3-6
Months
1.1M
USD
7
6-9
Months
1.0M
USD
9
0-12
Months
1.3M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
336.9M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 133.13% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
373.9K
Volume
2
6-9
Months
2.0M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
8.3M
Volume
Months
6-9
5
3.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
140.4K
USD
4
3-6
Months
1.1M
USD
7
6-9
Months
1.0M
USD
9
0-12
Months
1.3M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
336.9M
USD
Months
0-12
0
0.0
USD
Months
IMVT News & Events
Events Timeline
2025-07-25 (ET)
2025-07-25
07:49:40
Immunovant 3M share Block Trade priced at $17.85

2025-07-24 (ET)
2025-07-24
17:18:49
Immunovant 3M share Block Trade; price range $17.85-$18.00

2025-05-29 (ET)
2025-05-29
07:08:08
Immunovant sees cash runway through GD readout expected in 2027

Sign Up For More Events
Sign Up For More Events
News
8.0
07-25NASDAQ.COMNoteworthy Friday Option Activity: IMVT, MOD, PCG
4.0
06-02TipRanks3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts
7.0
05-29PRnewswireIMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm
Sign Up For More News
People Also Watch

TPH
Tri Pointe Homes Inc (Delaware)
31.590
USD
-0.44%

GPOR
Gulfport Energy Corp
168.330
USD
-2.90%

HTGC
Hercules Capital Inc
19.440
USD
+0.05%

OR
OR Royalties Inc
27.920
USD
+0.07%

CRSP
CRISPR Therapeutics AG
64.760
USD
-1.97%

SSL
Sasol Ltd
5.120
USD
-4.66%

CLSK
CleanSpark Inc
11.820
USD
-4.21%

CRNX
Crinetics Pharmaceuticals Inc
30.990
USD
+1.91%

IGT
International Game Technology PLC
0
USD
+2.95%

ZI
Zoominfo Technologies Inc
0
USD
+9.31%
FAQ

What is Immunovant Inc (IMVT) stock price today?
The current price of IMVT is 16.95 USD — it has decreased -7.48 % in the last trading day.

What is Immunovant Inc (IMVT)'s business?

What is the price predicton of IMVT Stock?

What is Immunovant Inc (IMVT)'s revenue for the last quarter?

What is Immunovant Inc (IMVT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Immunovant Inc (IMVT)'s fundamentals?

How many employees does Immunovant Inc (IMVT). have?
